Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.
Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL. Lamichhane P, et al. Among authors: bahr d. Cancer Res. 2017 Dec 1;77(23):6667-6678. doi: 10.1158/0008-5472.CAN-17-0740. Epub 2017 Oct 9. Cancer Res. 2017. PMID: 28993412 Free PMC article.
Immunotherapies in rare cancers.
Vivekanandhan S, Bahr D, Kothari A, Ashary MA, Baksh M, Gabriel E. Vivekanandhan S, et al. Among authors: bahr d. Mol Cancer. 2023 Feb 1;22(1):23. doi: 10.1186/s12943-023-01720-2. Mol Cancer. 2023. PMID: 36726126 Free PMC article. Review.
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI, Dutta N, Necela BM, Cannon MJ, Block MS, Knutson KL. Luo Y, et al. Among authors: bahr da. J Immunother Cancer. 2023 Nov;11(11):e007661. doi: 10.1136/jitc-2023-007661. J Immunother Cancer. 2023. PMID: 37918918 Free PMC article.
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
Gabriel EM, Necela B, Bahr D, Vivekanandhan S, Shreeder B, Bagaria S, Knutson KL. Gabriel EM, et al. Among authors: bahr d. Res Sq [Preprint]. 2024 Apr 3:rs.3.rs-4004491. doi: 10.21203/rs.3.rs-4004491/v1. Res Sq. 2024. Update in: Sci Rep. 2024 Oct 19;14(1):24545. doi: 10.1038/s41598-024-76209-z PMID: 38645250 Free PMC article. Updated. Preprint.
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.
Krause N, Derad C, von Glasenapp B, Riemann-Lorenz K, Temmes H, van de Loo M, Friede T, Asendorf T, Heesen C; POWER@MS1 study group. Krause N, et al. Mult Scler Relat Disord. 2023 Nov;79:105043. doi: 10.1016/j.msard.2023.105043. Epub 2023 Oct 5. Mult Scler Relat Disord. 2023. PMID: 37839367 Free article. Clinical Trial.
64 results